SARATOGA, Calif.--(BUSINESS WIRE)--In an analysis of 150 putative myelin repair targets identified by the Myelin Repair Foundation (MRF) collaborative research team since 2004, more than 40 already have approved drugs on the market or are currently in clinical development by several biopharmaceutical companies for non-Multiple Sclerosis disease indications (See Figures 1 & 2.). The analysis also shows that 31 additional MRF targets are in the discovery process or preclinical stage for other indications.
The analysis of publicly available data was conducted by the MRF Drug Discovery Advisory Board of outside biopharmaceutical experts to aid the Foundation in prioritizing the overwhelming number of targets generated in its funded laboratories at Stanford University, the University of Chicago, Northwestern University, Case Western Reserve University, University of California-San Francisco and the University of Melbourne, Victoria, Australia.
“From day one, we set out to find ways to accelerate the time to market for this next generation MS therapy. This analysis gives us critical information to engage pharma partners sooner with a portfolio of targets that are at different stages of development,” said MRF President and Founder Scott Johnson.
Says Dr. Jay Tung, MRF Vice President of Drug Discovery: “We have known for some time that our labs were producing myelin repair targets at a rapid rate, but this analysis tells us that quite a few of them are farther down the pipeline than we were aware of. More importantly, it identifies several companies that would make optimal partners for us to fast track one of our programs to the clinic.”
About the Myelin Repair Foundation
The Myelin Repair Foundation (MRF) ‐ http://www.myelinrepair.org ‐ is a Northern California‐based, non‐profit research organization focused on accelerating discovery and development of myelin repair therapeutics for multiple sclerosis. Its Accelerated Research Collaboration™ (ARC™) model is designed to optimize the entire process of medical research, drug development and the delivery of patient treatments.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6565155&lang=en